Список литературы

1. C., Harper J.I., Hoeger P.H. Infantile haemangioma//The Lancet. Lancet, 2017. Vol. 390, N 10089. P. 85 - 94.

2. Darrow D.H.D.H. et al. Diagnosis and management of infantile Hemangioma//Pediatrics. Pediatrics, 2015. Vol. 136, N 4. P. e1060 - e1104.

3. Drolet B.A., Swanson E.A., Frieden I.J. Infantile Hemangiomas: An Emerging Health Issue Linked to an Increased Rate of Low Birth Weight Infants//J. Pediatr. J Pediatr, 2008. Vol. 153, N 5.

4. Frieden I.J. et al. Infantile hemangiomas: Current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas//Pediatric Dermatology. Pediatr Dermatol, 2005. Vol. 22, N 5. P. 383 - 406.

5. Haggstrom A.N. et al. Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment//Pediatrics. Pediatrics, 2006. Vol. 118, N 3. P. 882 - 887.

6. C. infantiles: dans le traitement//Archives de Pediatrie. Arch Pediatr, 2013. Vol. 20, N 5. P. 517 - 522.

7. Enjolras O. Angiomes//Revue du Praticien. Rev Prat, 2003. Vol. 53, N 8. P. 899 - 905.

8. Stefan D. et al. : de la physiologie therapeutique.// Urgences. 2000. Vol. 9. P. 534 - 544.

9. Presta M. et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis//Cytokine Growth Factor Rev. Cytokine Growth Factor Rev, 2005. Vol. 16, N 2 SPEC. ISS. P. 159 - 178.

10. C., A. des dans les capillaires infantiles: signification physiopathologique et //Ann. Dermatol. Venereol. Ann Dermatol Venereol, 2008. Vol. 135, N 12. P. 860 - 862.

11. Wassef M. et al. Vascular tumours and malformations, classification, pathology and imaging//Ann. Chir. Plast. Esthet. Elsevier Masson SAS, 2006. Vol. 51, N 4 - 5. P. 263 - 281.

12. Drolet B.A. et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference//Pediatrics. Pediatrics, 2013. Vol. 131, N 1. P. 128 - 140.

13. C., Sans-Martin V. Infantile hemangioma//Press. Medicale. Elsevier Masson SAS, 2010. Vol. 39, N 4. P. 499 - 510.

14. Enjolras O., Mulliken J.B. Vascular tumors and vascular malformations (new issues)//Adv. Dermatol. 1997. Vol. 13. P. 375 - 423.

15. Wechsler J. et al. Pathologie tumorale. P. 697.

16. Casanova D. et al. Les : aspects cliniques//Ann. Chir. Plast. Esthet. Elsevier Masson SAS, 2006. Vol. 4 - 5, N 51. P. 287 - 292.

17. Philandrianos C. et al. Diagnosis and management of vascular anomalies//Ann. Chir. Plast. Esthet. Elsevier Masson SAS, 2011. Vol. 56, N 3. P. 241 - 253.

18. Bianchi A. et al. Congenital ulcerated lip hemangioma treated with a cleft lip technique//Cleft Palate-Craniofacial J. Cleft Palate Craniofac J, 2017. Vol. 54, N 2. P. 231 - 234.

19. Nakayama H. CLINICAL AND HISTOLOGICAL STUDIES OF THE CLASSIFICATION AND THE NATURAL COURSE OF THE STRAWBERRY MARK//J. Dermatol. John Wiley & Sons, Ltd, 1981. Vol. 8, N 4. P. 277 - 291.

20. Waner M. et al. The nonrandom distribution of facial hemangiomas//Arch. Dermatol. Arch Dermatol, 2003. Vol. 139, N 7. P. 869 - 875.

21. Haggstrom A.N. et al. Risk for PHACE syndrome in infants with large facial hemangiomas//Pediatrics. Pediatrics, 2010. Vol. 126, N 2.

22. Chiller K.G., Passaro D., Frieden I.J. Hemangiomas of infancy: Clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex//Arch. Dermatol. Arch Dermatol, 2002. Vol. 138, N 12. P. 1567 - 1576.

23. Metry D.W. et al. The many faces of PHACE syndrome//J. Pediatr. J Pediatr, 2001. Vol. 139, N 1. P. 117 - 123.

24. C., Prey S., Ezzedine K. Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities//J. Eur. Acad. Dermatology Venereol. J Eur Acad Dermatol Venereol, 2011. Vol. 25, N 11. P. 1245 - 1253.

25. Chang L.C. et al. Growth characteristics of infantile hemangiomas: implications for management//Pediatrics. Pediatrics, 2008. Vol. 122, N 2. P. 360 - 367.

26. Baselga E. et al. Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy//JAMA dermatology. JAMA Dermatol, 2016. Vol. 152, N 11. P. 1239 - 1243.

27. Krowchuk D.P. et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas//Pediatrics. 2019. Vol. 143, N 1.

28. Haggstrom A.N. et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development//Pediatrics. Pediatrics, 2006. Vol. 117, N 3. P. 698 - 703.

29. Chamlin S.L. et al. Multicenter prospective study of ulcerated hemangiomas//J. Pediatr. J Pediatr, 2007. Vol. 151, N 6.

30. Dubois J. et al. Orbit and eyelid hemangiomas: Is there a relationship between location and ocular problems?//J. Am. Acad. Dermatol. 2006. Vol. 55, N 4. P. 614 - 619.

31. Holland K.E., Drolet B.A. Infantile Hemangioma//Pediatric Clinics of North America. Pediatr Clin North Am, 2010. Vol. 57, N 5. P. 1069 - 1083.

32. Rahbar R. et al. The biology and management of subglottic hemangioma; past, present, future//Laryngoscope. Laryngoscope, 2004. Vol. 114, N 11. P. 1880 - 1891.

33. Badi A.N. et al. Histopathologic and immunophenotypic profile of subglottic hemangioma: Multicenter study//Int. J. Pediatr. Otorhinolaryngol. Int J Pediatr Otorhinolaryngol, 2009. Vol. 73, N 9. P. 1187 - 1191.

34. Christison-Lagay E.R. et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry//J. Pediatr. Surg. J Pediatr Surg, 2007. Vol. 42, N 1. P. 62 - 68.

35. Levy A.D. et al. Gastrointestinal hemangiomas: Imaging findings with pathologic correlation in pediatric and adult patients//Am. J. Roentgenol. AJR Am J Roentgenol, 2001. Vol. 177, N 5. P. 1073 - 1081.

36. Константинова Н.К. et al. Случай успешного лечения редкой патологии - LUMBAR синдрома//Педиатрия. 2020. Vol. 99, N 4. P. 279 - 282.

37. Rotter A. et al. PHACE syndrome: clinical manifestations, diagnostic criteria, andmanagement//An. Bras. Dermatol. Sociedade Brasileira de Dermatologia, 2018. Vol. 93, N 3. P. 405.

38. Garzon M.C. et al. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations//J. Pediatr. J Pediatr, 2016. Vol. 178. P. 24 - 33.e2.

39. Kulungowski A.M. et al. Lessons from a liver hemangioma registry: Subtype classification//J. Pediatr. Surg. J Pediatr Surg, 2012. Vol. 47, N 1. P. 165 - 170.

40. Huang S.A. et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas//N. Engl. J. Med. N Engl J Med, 2000. Vol. 343, N 3. P. 185 - 189.

41. Konrad D., Ellis G., Perlman K. Spontaneous Regression of Severe Acquired Infantile Hypothyroidism Associated with Multiple Liver Hemangiomas//Pediatrics. Pediatrics, 2003. Vol. 112, N 6 I. P. 1424 - 1426.

42. Bauland C.G. et al. Untreated hemangiomas: growth pattern and residual lesions//Plast. Reconstr. Surg. Plast Reconstr Surg, 2011. Vol. 127, N 4. P. 1643 - 1648.

43. Maruani A. Angiomes//. 6e . 2011. P. 252 - 255.

44. Iacobas I. et al. Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring//J. Pediatr. J Pediatr, 2018. Vol. 203. P. 294 - 300. e2.

45. Grant A.M. et al. Rethinking Blood Testing in Pediatric Cancer Patients: A Quality Improvement Approach//Pediatr. Qual. Saf. Wolters Kluwer Health, 2022. Vol. 7, N 3. P. e552.

46. Babiak-Choroszczak L. et al. Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas//Adv. Clin. Exp. Med. Adv Clin Exp Med, 2019. Vol. 28, N 3. P. 381 - 390.

47. Ainipully A.M. et al. Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome//J. Indian Assoc. Pediatr. Surg. Wolters Kluwer -- Medknow Publications, 2019. Vol. 24, N 3. P. 170.

48. Sethuraman G., Yenamandra V., Gupta V. Management of infantile hemangiomas: current trends//J. Cutan. Aesthet. Surg. J Cutan Aesthet Surg, 2014. Vol. 7, N 2. P. 75.

49. Sebaratnam D.F. et al. Infantile hemangioma. Part 2: Management//J. Am. Acad. Dermatol. J Am Acad Dermatol, 2021. Vol. 85, N 6. P. 1395 - 1404.

50. Bongsebandhu-Phubhakdi C., Tempark T., Supornsilpchai V. Endocrine manifestations of PHACE syndrome//J. Pediatr. Endocrinol. Metab. J Pediatr Endocrinol Metab, 2019. Vol. 32, N 8. P. 797 - 802.

51. Kaur K., Adamski J.J. Fecal Occult Blood Test//StatPearls. StatPearls Publishing, 2022.

52. ElHassan N.O. et al. A Preterm Infant with Abdominal Distension and Bloody Stools//J. Pediatr. J Pediatr, 2019. Vol. 205. P. 289 - 289. e1.

53. Ameen N.N. Gastrointestinal and mesenteric hemangioma; a rare case presentation//J. Sulaimani Med. Coll. 2018. Vol. 8, N 2. P. 127 - 129.

54. Bourrat E. et al. PELVIS/SACRAL syndrome avec et bride amniotique//Ann. Dermatol. Venereol. Elsevier Masson, 2008. Vol. 135, N 12. P. 855 - 859.

55. Nijmegen R. Consensus document for the treatment of infantile haemangiomas. 2017. 20 p.

56. Elajmi A. et al. Prise en charge des anomalies vasculaires chez l'enfant//Ann. Chir. Plast. . Elsevier Masson, 2016. Vol. 61, N 5. P. 480 - 497.

57. Ding A.A. et al. Role of ultrasound in diagnosis and differential diagnosis of deep infantile hemangioma and venous malformation//J. Vasc. surgery. Venous Lymphat. Disord. J Vasc Surg Venous Lymphat Disord, 2019. Vol. 7, N 5. P. 715 - 723.

58. Delmotte N. et al. Mise au point sur le traitement de du nourrisson par //Therapies. Elsevier, 2012. Vol. 67, N 3. P. 257 - 265.

59. Carinci S. et al. A case of congenital hypothyroidism in PHACE syndrome//J. Pediatr. Endocrinol. Metab. J Pediatr Endocrinol Metab, 2012. Vol. 25, N 5 - 6. P. 603 - 605.

60. Bongsebandhu-Phubhakdi C. et al. A case of PHACE syndrome with growth hormone deficiency and abnormal thyroid functions//J. Pediatr. Endocrinol. Metab. J Pediatr Endocrinol Metab, 2019. Vol. 32, N 11.

61. Eschard C. infantiles: quand explorer et //Ann. Dermatol. Venereol. Elsevier Masson, 2015. Vol. 142, N 8 - 9. P. 476 - 482.

62. Horii K.A. et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas//Pediatr. Dermatol. Pediatr Dermatol, 2011. Vol. 28, N 3. P. 245 - 253.

63. Lacoste A., C. Formation continue Clinique miliaire//Ann Dermatol Venereol. 2007. Vol. 134. P. 694 - 702.

64. Canty K.M. et al. Multiple cutaneous and hepatic hemangiomas in infants//South. Med. J. South Med J, 2014. Vol. 107, N 3. P. 159 - 164.

65. Luu J., Cotton C.H. Hemangioma Genetics and Associated Syndromes//Dermatol. Clin. Dermatol Clin, 2022. Vol. 40, N 4. P. 393 - 400.

66. Raphael M.F. et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study//J. Am. Acad. Dermatol. J Am Acad Dermatol, 2015. Vol. 72, N 3. P. 465 - 472.

67. Cushing S.L. et al. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas//Otolaryngol. Head. Neck Surg. Otolaryngol Head Neck Surg, 2011. Vol. 144, N 1. P. 78 - 84.

68. Frongia G. et al. Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants//World J. Pediatr. World J Pediatr, 2018. Vol. 14, N 3. P. 254 - 258.

69. Zimmermann A.P. et al. Propranolol therapy for infantile haemangiomas: review of the literature//Int. J. Pediatr. Otorhinolaryngol. Int J Pediatr Otorhinolaryngol, 2010. Vol. 74, N 4. P. 338 - 342.

70. Kassarjian A. et al. Infantile hepatic hemangiomas: clinical and imaging findings and their correlation with therapy//AJR. Am. J. Roentgenol. AJR Am J Roentgenol, 2004. Vol. 182, N 3. P. 785 - 795.

71. Kitami M. Diffusion-weighted imaging as a routine MRI protocol for the evaluation of "infantile hemangioma"//Clin. Imaging. Clin Imaging, 2017. Vol. 46. P. 121.

72. Park H.J. et al. Ultrasound and MRI findings as predictors of propranolol therapy response in patients with infantile hemangioma//PLoS One. PLoS One, 2021. Vol. 16, N 3.

73. Шептий О.В., Круглова Л.С. Младенческая гемангиома: классификация, клиническая картина и методы коррекции//Российский журнал кожных и венерических болезней. 2016. Vol. 19, N 3. P. 178 - 183.

74. Хачатрян Л.А. et al. Терапия детей с синдромом Казабаха-Мерритт//Педиатрия. 2018. Vol. 97, N 4. P. 125 - 134.

75. Хачатрян Л.А., Николаева Д.М., Щербаков А.П. Когда болезнь выходит за пределы кожи - изменения на коже могут быть признаком системного заболевания//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020. Vol. 19, N 3. P. 95 - 104.

76. Bandera A.I. et al. Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment//J. Am. Acad. Dermatol. J Am Acad Dermatol, 2021. Vol. 85, N 6. P. 1379 - 1392.

77. Hess C.P. et al. Cervical and intracranial arterial anomalies in 70 patients with PHACE syndrome//AJNR. Am. J. Neuroradiol. AJNR Am J Neuroradiol, 2010. Vol. 31, N 10. P. 1980 - 1986.

78. Heyer G.L. et al. The cerebral vasculopathy of PHACES syndrome//Stroke. Stroke, 2008. Vol. 39, N 2. P. 308 - 316.

79. Prada F. et al. Complex Aortic Coarctation and PHACE Syndrome//Rev. Cardiol. (English Ed. Elsevier, 2010. Vol. 63, N 11. P. 1367 - 1370.

80. Buckmiller L., Dyamenahalli U., Richter G.T. Propranolol for airway hemangiomas: case report of novel treatment//Laryngoscope. Laryngoscope, 2009. Vol. 119, N 10. P. 2051 - 2054.

81. Kveton J.F., Pillsbury H.C. Conservative Treatment of Infantile Subglottic Hemangioma With Corticosteroids//Arch. Otolaryngol. American Medical Association, 1982. Vol. 108, N 2. P. 117 - 119.

82. Drolet B.A. et al. Gastrointestinal bleeding in infantile hemangioma: a complication of segmental, rather than multifocal, infantile hemangiomas//J. Pediatr. J Pediatr, 2012. Vol. 160, N 6.

83. Hoornweg M.J. et al. Malignant differential diagnosis in children referred for infantile hemangioma//Ann. Plast. Surg. Ann Plast Surg, 2015. Vol. 74, N 1. P. 43 - 46.

84. Хачатрян Л.А., Николаева Д.М. Современная терапия инфантильных гемангиом//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021. Vol. 20, N 2. P. 156 - 167.

85. Hoeger P.H.P.H. et al. Treatment of infantile haemangiomas: recommendations of a European expert group//Eur. J. Pediatr. Eur J Pediatr, 2015. Vol. 174, N 7. P. 855 - 865.

86. Marqueling A.L. et al. Propranolol and infantile hemangiomas four years later: a systematic review//Pediatr. Dermatol. Pediatr Dermatol, 2013. Vol. 30, N 2. P. 182 - 191.

87. Liu X. et al. Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis//PLoS One. Public Library of Science, 2015. Vol. 10, N 9.

88. Enjolras O. et al. [Vincristine treatment for function- and life-threatening infantile hemangioma]//Arch. Pediatr. Arch Pediatr, 2004. Vol. 11, N 2. P. 99 - 107.

89. Хачатрян Л.А. et al. Новые подходы к решению старой проблемы//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2022. Vol. 21, N 1. P. 122 - 135.

90. Lie E., K.B. Corticosteroids as an adjunct to propranolol for infantile haemangiomas complicated by recalcitrant ulceration//Br. J. Dermatol. Br J Dermatol, 2017. Vol. 176, N 4. P. 1064 - 1067.

91. Boon L.M. et al. Medical treatment of juvenile hemangiomas//Ann. Chir. Plast. Esthet. Ann Chir Plast Esthet, 2006. Vol. 51, N 4 - 5. P. 310 - 320.

92. Breur J.M.P.J.J.M. et al. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report//Pediatr. Dermatol. Pediatr Dermatol, 2011. Vol. 28, N 2. P. 169 - 171.

93. M.F. et al. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas//J. Am. Acad. Dermatol. J Am Acad Dermatol, 2011. Vol. 65, N 2. P. 420 - 421.

94. . et al. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study//J. Am. Acad. Dermatol. J Am Acad Dermatol, 2014. Vol. 70, N 6. P. 1045 - 1049.

95. Ji Y. et al. Oral atenolol therapy for proliferating infantile hemangioma: A prospective study//Medicine (Baltimore). Medicine (Baltimore), 2016. Vol. 95, N 24.

96. De Graaf M. et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group//J. Plast. Reconstr. Aesthet. Surg. J Plast Reconstr Aesthet Surg, 2013. Vol. 66, N 12. P. 1732 - 1740.

97. K. et al. Topical Timolol Maleate Treatment of Infantile Hemangiomas//Pediatrics. 2016. Vol. 138, N 3.

98. Chan H. et al. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds//Pediatrics. Pediatrics, 2013. Vol. 131, N 6.

99. Borok J. et al. Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial//Br. J. Dermatol. Br J Dermatol, 2018. Vol. 178, N 1. P. e51 - e52.

100. Hartmann F. et al. Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children//J. Eur. Acad. Dermatol. Venereol. J Eur Acad Dermatol Venereol, 2017. Vol. 31, N 8. P. 1372 - 1379.

101. Zhong S.X. et al. Infantile Hemangioma: Clinical Characteristics and Efficacy of Treatment with the Long-Pulsed 1,064-nm Neodymium-Doped Yttrium Aluminum Garnet Laser in 794 Chinese Patients//Pediatr. Dermatol. Pediatr Dermatol, 2015. Vol. 32, N 4. P. 495 - 500.

102. Chinnadurai S., Sathe N.A., Surawicz T. Laser treatment of infantile hemangioma: A systematic review//Lasers Surg. Med. Lasers Surg Med, 2016. Vol. 48, N 3. P. 221 - 233.

103. Enjolras O., Picard A., Soupre V. Congenital haemangiomas and other rare infantile vascular tumours//Ann. Chir. Plast. Esthet. Elsevier Masson SAS, 2006. Vol. 51, N 4 - 5. P. 339 - 346.

104. Berenguer B. et al. Rapidly involuting congenital hemangioma: clinical and histopathologic features//Pediatr. Dev. Pathol. Pediatr Dev Pathol, 2003. Vol. 6, N 6. P. 495 - 510.

105. North P.E. et al. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma//Arch. Dermatol. Arch Dermatol, 2001. Vol. 137, N 12. P. 1607 - 1620.

106. Rodriguez V. et al. Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience//J. Pediatr. Hematol. Oncol. J Pediatr Hematol Oncol, 2009. Vol. 31, N 7. P. 522 - 526.

107. Ryan C. et al. Kasabach-Merritt phenomenon: a single centre experience//Eur. J. Haematol. Eur J Haematol, 2010. Vol. 84, N 2. P. 97 - 104.

108. Croteau S.E. et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals//J. Pediatr. J Pediatr, 2013. Vol. 162, N 1. P. 142 - 147.

109. Satter E.K., Graham B.S., Gibbs N.F. Congenital tufted angioma//Pediatr. Dermatol. Pediatr Dermatol, 2002. Vol. 19, N 5. P. 445 - 447.

110. Хачатрян Л.А., Клецкая И.С., Орехова Е.В. Синдромальная венозная мальформация - диссеминированный венозный ангиоматоз Бинаю//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019. Vol. 18, N 3. P. 78 - 87.

111. Starkey E., Shahidullah H. Propranolol for infantile haemangiomas: A review//Archives of Disease in Childhood. Arch Dis Child, 2011. Vol. 96, N 9. P. 890 - 893.

112. Biesbroeck L., Brandling-Bennett H.A. Propranolol for infantile haemangiomas: review of report of a consensus conference//Arch. Dis. Child. Educ. Pract. Ed. Arch Dis Child Educ Pract Ed, 2014. Vol. 99, N 3. P. 95 - 97.

113. Thaivalappil S. et al. Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants With Hemangiomas//JAMA Otolaryngol. Neck Surg. American Medical Association, 2013. Vol. 139, N 10. P. 1026 - 1031.

114. Greenberger S., Bischoff J. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor//Cold Spring Harb. Perspect. Med. Cold Spring Harb Perspect Med, 2011. Vol. 1, N 1.